Vanguard Capital Management
BNGO icon

Vanguard Capital Management’s Bionano Genomics BNGO Stock Holding History

Vanguard Capital Management’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93.1K Buy
82,388
+14,279
+21% +$17.2K ﹤0.01% 3882
2026
Q1 		$79.7K Buy
+68,109
New +$87.3K ﹤0.01% 3881

Other funds holding BNGO

GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CAM
Carret Asset Management New York $1.14B AUM 35.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $91.8B AUM 38.24% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
EGM
Engineers Gate Manager New York $7.71B AUM 24.88% 1-Year Est. Return

Vanguard Capital Management's BNGO Position: Q2 2026 in Review

Vanguard Capital Management increased its Bionano Genomics (BNGO) stake by 21% in Q2 2026, buying an estimated $17.2K and bringing the position to 82,388 shares worth $93.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3882.

Vanguard Capital Management first reported a position in BNGO in Q1 2026 and has held it in 2 quarters since. 34 funds tracked by Wall St. Rank hold BNGO as of Q2 2026.

  • Vanguard Capital Management held 82,388 shares of Bionano Genomics worth $93.1K as of Q2 2026.
  • Vanguard Capital Management bought 14,279 Bionano Genomics shares in Q2 2026, an estimated $17.2K.
  • Bionano Genomics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3882 holding.
  • Vanguard Capital Management first reported a position in Bionano Genomics in Q1 2026 and has held it in 2 quarters since.
  • 34 funds tracked by Wall St. Rank held Bionano Genomics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.